Murphy was appointed as Chief Financial Officer on May 11, 2026. His biographical information is set forth below. On April 20, 2026, we distributed all outstanding shares of common stock of our subsidiary First Tracks Biotherapeutics, Inc.

filing / Jun 29, 2026 / receipt

In connection with the Spin-Off (as defined below), Eric Loumeau, the former Chief Legal Officer, separated from the Company as an executive officer and Paul Lizzul, M.D., Ph.D., the former Chief Medical Officer and Dennis Mulroy, the former Chief Financial Officer, separated from the Company, effective as of April 20, 2026.

filing / Jun 29, 2026 / receipt

(aa) Overhead or other expense reduction; (bb) Credit rating; (cc) Strategic plan development and implementation; (dd) Succession plan development and implementation; (ee) Improvement in workforce diversity; (ff) Customer indicators and/or satisfaction; (gg) New product invention or innovation; (hh) Attainment of research and development milestones; (ii) Improvements in productivity; (jj) Bookings;

filing / Jun 29, 2026 / receipt

capital; cash flow (including free cash flow or operating cash flows); cash conversion cycle; economic value added; individual confidential business objectives; contract awards or backlog; overhead or other expense reduction; credit rating; strategic plan development and implementation; succession plan development and implementation; improvement in workforce diversity; customer indicators and/or satisfaction; new pro

filing / Jun 29, 2026 / receipt

Other general and administrative expenses include allocated facility-related costs not otherwise included in research and development expenses, travel expenses, transaction costs, and professional fees for auditing, tax, and legal services.

filing / May 12, 2026 / receipt

If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives.

filing / May 12, 2026 / receipt

Reduced prices and reimbursement rates due to the actions of governments, payors, or competition or other healthcare cost containment initiatives such as restrictions on use, may negatively impact royalties generated under the GSK Agreement.

filing / May 12, 2026 / receipt